宋桢

[摘要] 目的 探讨分析糖尿病周围神经病变（DPN）采用评价依帕司他的临床治疗有效性和安全性。方法 选取2017年2月—2018年2月在该院接受药物治疗的糖尿病周围神经病变106例患者作为研究对象，采用随机分组的方式，分为对照组和试验组，采用甲钴胺的患者设为对照组，采用依帕司他的患者设为试验组，比对两组患者临床症状的控制情况、用药前后神经传导的改善情况以及药物副作用的发生情况。结果 试验组患者的总有效（92.45%）与对照组患者的总有效（60.38%）相比明显较高，差异有统计学意义（P<0.05）；两组患者经用药后的感觉神经传导速度和运动神经传导速度较用药前的相比明显加快，差异有统计学意义（P<0.05）；试验组患者用药后的腓总神经、桡神经以及正中神经传导速度与对照组患者用药后的相比明显较好，差异有统计学意义（P<0.05）；试验组患者的副作用发生率（7.55%）与对照组患者的不良反应发生率（30.19%）相比明显较低，差异有统计学意义（P<0.05）。结论 依帕司他可以有效改善糖尿病患者周围神经病变的临床症状，缓解患者的神经传导速度，降低临床用药的不安全性。

[关键词] 糖尿病；周围神经病变；依帕司他；有效性；安全性

[中图分类号] R587.1 [文献标识码] A [文章编号] 1672-4062（2018）04（b）-0186-03

Evaluation on Effectiveness and Safety of Epalrestat in Treatment of DPN

SONG Zhen

Ningbo Jinzhou District Baizhang Street Health Service Center， Ningbo， Zhejiang Province， 315040 China

[Abstract] Objective To study and analyze the effectiveness and safety of epalrestat in treatment of DPN. Methods 106 cases of DPN patients treated in our hospital from February 2017 to February 2018 were selected as the research objects and randomly divided into two groups， the control group and the test group were respectively treated with mecobalamine and epalrestat， and the control of clinical symptoms， improvement of nerve conduction before and after medication and occurrence of side effect of drugs were compared between the two groups. Results The total treatment effective rate in the test group was obviously higher than that in the control group（92.45% vs 60.38%）， and the difference was statistically significant（P<0.05）， and the sensory nerve conduction rate and motor nerve conduction rate of the two groups after medication were obviously quickened and the differences were statistically significant（P<0.05）， and the common peroneal nerve， radial nerve and median nerve conduction velocity after medication in the test group were obviously better than those in the control group， and the differences were statistically significant（P<0.05）， and the incidence rate of side effect in the test group was obviously lower than that in the control group（7.55% vs 30.19%）， and the difference was statistically significant（P<0.05）. Conclusion The epalrestat can effectively improve the clinical symptoms of peripheral neuropathy of diabetes patients， relieve the nerve conduction rate， and reduce the insecurity of clinical medication.

[Key words] Diabetes； Peripheral neuropathy； Epalrestat； Effectiveness； Safety

糖尿病已成為全世界最为关注的慢性内分泌疾病，会给患者的身体和心理带来长久的不良影响[1]。该病会诱发患者的机体的其他器官或组织发生病变，多次给患者的机体带来的损伤和疼痛，进而会给患者的心理带来一定程度的创伤[2]。周围神经病变是糖尿病病变中常见的病种之一，该病会影响患者的神经功能，带来肢体上的麻木、疼痛等，甚至会对患者的生命安全造成威胁[3]。依帕司他和甲钴胺为该疾病的治疗的高应用率药物，为探究何种药物治疗方案疗效更佳，现选取该院在2017年2月—2018年2月期间收治的106例糖尿病周围神经病变作为研究对象行临床对比分析，现将结果报道如下。

1 资料与方法

1.1 一般资料

将该院收治的106例糖尿病周围神经病变患者作为研究对象，年龄43～69岁，平均年龄（56.43±26.82）岁。……